The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Bisphosphonates induce apoptosis in human breast cancer cell lines
Open accessAbstract
Breast cancer has a prodigious capacity to metastasize to bone. In women with advanced breast cancer and bone metastases, bisphosphonates reduce the incidence of hypercalcaemia and skeletal morbidity. Recent clinical findings suggest that some bisphosphonates reduce the tumour burden in bone with a consequent increase in survival, raising the possibility that bisphosphonates may have a direct effect on breast cancer cells. We have investigated the in vitro effects of bisphosphonates zoledronate, pamidronate, clodronate and EB 1053 on growth, viability and induction of apoptosis in three human breast cancer cell lines (MDA-MB-231, Hs 578T and MCF-7). Cell growth was monitored by crystal violet dye assay, and cell viability was quantitated by MTS dye reduction. Induction of apoptosis was determined by identification of morphological features of apoptosis using time-lapse videomicroscopy, identifying morphological changes in nucleis using Hoechst staining, quantitation of DNA fragmentation, level of expression of bcl-2 and bax proteins and identification of the proteolytic cleavage of Poly (ADP)-ribose polymerase (PARP). All four bisphosphonates significantly reduced cell viability in all three cell lines. Zoledronate was the most potent bisphosphonate with IC50 values of 15, 20 and 3 microM respectively in MDA-MB-231, MCF-7 and Hs 578T cells. Corresponding values for pamidronate were 40, 35 and 25 microM, whereas clodronate and EB 1053 were more than two orders of magnitude less potent. An increase in the proportion of cells having morphological features characteristic of apoptosis, characteristic apoptotic changes in the nucleus, time-dependent increase in the percentage of fragmented chromosomal DNA, down-regulation in bcl-2 protein and proteolytic cleavage of PARP, all indicate that bisphosphonates have direct anti-tumour effects on human breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
Wyllie, A. H. (1980) · Nature · doi:10.1038/284555a0 · Cited by 4,504
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., & Earnshaw, W. C. (1994) · Nature · doi:10.1038/371346a0 · Cited by 2,562
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., & Dixit, V. M. (1995) · Cell · doi:10.1016/0092-8674(95)90541-3 · Cited by 2,367
Bcl-2 and the regulation of programmed cell death
Reed, J. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.1.1 · Cited by 2,305
Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death
Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B., & Korsmeyer, S. J. (1995) · Cell · doi:10.1016/0092-8674(95)90411-5 · Cited by 2,100
Kaufmann, S. H., Desnoyers, S., Ottaviano, Y. L., Davidson, N. E., & Poirier, G. G. (1993) · PubMed · Cited by 1,889
Use of an Aqueous Soluble Tetrazolium/Formazan Assay for Cell Growth Assays in Culture
Cory, A. H., Owen, T. C., Barltrop, J. A., & Cory, J. G. (1991) · Cancer Communications · doi:10.3727/095535491820873191 · Cited by 1,519
Bossy‐Wetzel, E., Newmeyer, D. D., & Green, D. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.37 · Cited by 1,225
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004 · cited 1×
“Sato et al (1991) have concluded that local concentration of bisphosphonate released from hydro apatite into the resorption space would be substantially higher t that present in the circulation and could reach 1000µM.”
BackgroundReduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Hortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Powell, G. J., Southby, J., Danks, J. A., Stillwell, R. G., Hayman, J., Henderson, M. A., Bennett, R. C., & Martin, T. J. (1991) · PubMed · Cited by 445
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity
Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2713086.x · Cited by 398
Hughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357
Golstein, P. (1997) · Science · doi:10.1126/science.275.5303.1081 · Cited by 347
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F. H., Delmas, P. D., & Clézardin, P. (1997) · PubMed · Cited by 343
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Luckman, S. P., Coxon, F. P., Ebetino, F. H., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1668 · Cited by 272
Altman, R. D., Johnston, C. C., Khairi, M. R. A., Wellman, H., Serafini, A. N., & Sankey, R. R. (1973) · New England Journal of Medicine · doi:10.1056/nejm197312272892601 · Cited by 248
Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
Selander, K. S., Mönkkönen, J., Karhukorpi, E. K., Härkönen, P., Hannuniemi, R., & Väänänen, H. K. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09541-0 · Cited by 237
Clodronate decreases the frequency of skeletal metastases in women with breast cancer
Kanis, J. A., Powles, T., Paterson, A. H. G., McCloskey, E. V., & Ashley, S. (1996) · Bone · doi:10.1016/s8756-3282(96)00285-2 · Cited by 224
Signal Transduction Pathways in Apoptosis
McConkey, D. J., & Orrenius, S. (1996) · STEM CELLS · doi:10.1002/stem.140619 · Cited by 222
Shipman, C. M., Croucher, P. I., Russell, R. G. G., Helfrich, M. H., & Rogers, M. J. (1998) · PubMed · Cited by 216
Dbaibo, G. S., Perry, D. K., Gamard, C. J., Platt, R., Poirier, G. G., Obeid, L. M., & Hannun, Y. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.481 · Cited by 207
Dr. Löwik, C. W. G. M., Van Der Pluijm, G., Van Der Wee-Pals, L. J. A., Van Treslong-De Groot, H. B., & Bijvoet, O. L. M. (1988) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650030210 · Cited by 191
Lin, J. H., Duggan, D. E., Chen, I. W., & Ellsworth, R. L. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08972-x · Cited by 163
Scanning electron microscopy in bone pathology: review of methods, potential and applications.
BOYDE, A., Maconnachie, E., Reid, S. A., Delling, G., & Mundy, G. R. (1986) · PubMed · Cited by 159
Caspases disrupt mitochondrial membrane barrier function
Marzo, I., Susín, S. A., Petit, P. X., Ravagnan, L., Brenner, C., Larochette, N., Zamzami, N., & Kroemer, G. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00424-4 · Cited by 153
Bisphosphonates as Anticancer Drugs
Mundy, G. R., & Yoneda, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390609 · Cited by 131
Coxon, F. P., Benford, H. L., Russell, R. G. G., et al. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13063-5 · Cited by 89
Intravenous Etidronate in the Management of Malignant Hypercalcemia
Ryzen, E. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360030089018 · Cited by 86
Hall, D. G., & Stoica, G. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090211 · Cited by 74
Effects of intravenous etidronate disodium on skeletal and calcium metabolism
Kanis, J. А., Urwin, G. H., Gray, R. E., Beneton, M. N. C., McCloskey, E. V., Hamdy, N. A. T., & Murray, S. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90488-8 · Cited by 72
Wosikowski, K., Küng, W., Hasmann, M., Löser, R., & Eppenberger, U. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530220 · Cited by 55
Vitale, M., Matola, T. D., Rossi, G., et al. (1999) · Endocrinology · doi:10.1210/endo.140.2.6494 · Cited by 45
Morphological, Biochemical, and Flow Cytometric Assays of Apoptosis
Martin, D., & Lenardo, M. J. (2000) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1413s49 · Cited by 44
Cited by
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Bisphosphonates: Preclinical Review
Green, J. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-3 · Cited by 405
Metadata
- Authors
- Senaratne, S. G., Pirianov, G., Mansi, J. L., Arnett, T. R., & Langrish, V
- Venue
- British Journal of Cancer
- Published
- 2000-04
- Volume
- 82
- Issue
- 8
- Pages
- 1459-1468
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2041868422
- Cited by
- 428
- References
- 45
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.